Behavioral Disorders Therapeutic Development Landscape Reviewed by GBI Research in Its In-Demand Report Available at MarketPublishers.com
24 Oct 2017 • by Natalie Aster
LONDON – Autism, also termed as complex developmental disability, is a neurological disease that has a bearing on a person’s ability to interact with others, communicate verbally and nonverbally, and is characterised by repetitive behaviours. Risk factors encompass children’s sex, familial history, fragile X syndrome (FXS), Tourette syndrome (TS) and epilepsy.
Obsessive-compulsive disorder (OCD) is an anxiety disorder that is characterised by unwanted thoughts and sensations (obsessions) in which a person urges to do repetitive behaviours. Symptoms comprise having reoccurring thoughts or mental; images about a variety of things, like fear of dirt, germs, or invaders, acts of violence, upsetting loved ones, doing the same rituals repeatedly like washing hands, checking if the door is locked, keeping unnecessary items, counting, or doing the same steps over and over again.
Attention deficit/hyperactivity disorder (ADHD) is a class of behavioral symptoms including poor attention, hyperactivity and impulsivity. ADHD’s symptoms encompass disorganised working habits, procrastination and incapability of holding attention on tasks or activities.
The size of these pipelines ranges from 8 products in OCD to 58 products in ADHD. Across all 3 of these disorders, transporters and receptors of neurotransmitters like dopamine, serotonin and glutamine, plus 7-transmembrane domain receptors and ion channels, are the most typical targets, closely mirroring the present-day treatment landscape of these indications.
In-demand research report “Behavioral Disorders Drug Development Pipeline Review, 2017” elaborated by GBI Research gives a comprehensive evaluation of the treatment landscape for autism, OCD and ADHD.
The study examines the total pipeline, with a sneak peek of all products in development for all three indications. It gives a granular assessment of the products in development, with a cutting-edge overview of each individual pipeline program in all indications discussed, and an exhaustive picture of up-to-the-minute updated information and milestones for each. The report discusses the companies and organisations operating in the pipeline today, and the products fielded by each of these. It gives an all-round understanding of the structure of the pipeline by molecular target, molecule type, MoA and RoA.
A full collection of the publisher’s research reports is at hand in GBI Research catalogue at MarketPublishers.com.